JasonDoiy/iStock Unreleased via Getty Images 23andMe (NASDAQ:ME), which is in the middle of an attempt by its CEO to take the DNA-testing company private, said it has shut down its therapeutics discovery business, resulting in the layoffs of 30 employees. The company noted that the elimination of the division should not have a material impact on its financials. The therapeutics development business is not impacted by the decision, and two programs in development will continue. Separately, 23andMe said it will launch a GLP-1 weight loss telehealth membership through its Lemonaid Health platform by the end of August. The company added the offering will allow customers to purchase either compounded versions of semaglutide, the active ingredient in Novo Nordisk's (NVO) Wegovy, or the brand-name version. In May, telehealth platform Hims & Hers Health (HIMS) said it was offering compounded semaglutide.